Reviva Pharmaceuticals reports 108 patients completed a trial for schizophrenia treatment, with topline data expected December 2024.Quiver AI SummaryReviva Pharmaceuticals Holdings, Inc. announced that...
Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at...
CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...